Breast Surgery

Genova, Italy

Breast Surgery

Genova, Italy
SEARCH FILTERS
Time filter
Source Type

Melvin J. Silverstein, M.D., Hoag Breast Center Medical Director and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery and Nirav Savalia, M.D., Director of Oncoplastic and Aesthetic Breast Surgery at Hoag, were among the faculty...


Hoag Physicians Selected to Teach Unique Breast Conserving Operative Technique at National Meeting for The American Society of Breast Surgeons Newport Beach, CA, May 01, 2017 --( This prestigious opportunity allowed Drs. Silverstein and Savalia to discuss and teach the Split Reduction, an operative technique developed and perfected at Hoag, for surgeons across the nation. Combining the principles of oncologic surgery with the techniques of plastic surgery, this technique alters the incision site on a patient’s breast to accommodate tumors that other oncologists said could not be removed without a mastectomy. “Hoag is the most advanced place in the world for saving breasts for patients who are told they need a mastectomy,” Dr. Silverstein said. “Women have so many treatment options, including lumpectomies and oncoplastic surgery to remove cancerous tumors while achieving optimal cosmetic and oncologic results. It is surprising that mastectomy is still the default surgical option for breast cancer treatment,” Dr. Savalia added. In addition, five research poster presentations were presented at the national meeting by Hoag faculty and USC/Hoag Breast Fellows on the following topics: A Comparison of Margin Width in DCIS Patients Treated with Breast Conserving Surgery Plus Whole Breast Radiation Therapy. Data supported the Consensus Guideline: 2 mm is an appropriate minimal margin width for patients with DCIS patients treated with breast conserving therapy plus whole breast radiation therapy. Analysis of data found a higher local recurrence rate with narrow surgical margins (< 2mm margins) at 31% compared with the adequately excised group (≥ 2mm margins) at 11%. Authors: Sadia Khan, DO, Program Advisor Hoag Breast Center, Melvin J. Silverstein, MD, Hoag Breast Center Medical Director and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, et al Excision alone for low risk Ductal Carcinoma In-Situ (DCIS) using University of Southern California/Van Nuys Prognostic Index (USC/VNPI). Findings confirm reports that whole breast radiation therapy (WBRT) may be safely omitted in patients with low-risk DCIS. Established the UCS/VNPI algorithm that quantifies five measurable prognostic factors (tumor size, margin width, nuclear grade, age and comedonecrosis) and aids in predicting local recurrence in conservatively treated patients. Authors: Nicole Zaremba, MD (2017 Muzzy Family Endowed Fellowship in Oncoplastic Breast Surgery at Hoag), et al Outcome After Local Invasive Recurrence: The Impact of Original Diagnosis of DCIS Versus Invasive Cancer. Found that patients with an original diagnosis of invasive breast cancer have higher probability of developing an invasive local recurrence when compared to patients with an original diagnosis of DCIS (42% versus 12%). Authors: Julie Wecsler, MD (USC/Hoag Breast Fellow), et al Four-Year Results of a Single Site X-Ray IORT Trial for Early Breast Cancer. Studied intraoperative radiotherapy (IORT) as a safe alternative to whole breast radiation (WBRT) for low-risk breast cancer patients. Found the rate of local ipsilateral breast tumor events is somewhat higher than those reported in WBRT patients but lower than those described in patients treated with excision alone. Authors: Melinda Epstein, Ph.D., et al Intraductal Papillomas: To Excise or Not Excise Authors: Sayee Kiran, MD (USC/Hoag Breast Fellow), et al This research was presented at the 18th Annual Meeting of the American Society of Breast Surgeons. Joining the Hoag Breast team at the national meeting was the winner of the 2017 International Scholarship in Breast Surgery Juan Cossa, M.D., Associate Professor of Surgery, Clinics Hospital of Montevideo, Uruguay. Dr. Cossa was selected by the American College of Surgeons (ACS) and the American Society of Breast Surgeons (ASBS) and chose to visit Hoag when given the opportunity to study at any cancer hospital in the United States. “It was an honor to have Dr. Cossa join our team and have the opportunity to teach him about oncoplastic surgery,” said Dr. Silverstein. “Hoag continues to pioneer innovative medical and surgical advancements and it’s a privilege to be able to share that knowledge with surgeons around the world.” Newport Beach, CA, May 01, 2017 --( PR.com )-- Melvin J. Silverstein, M.D., Hoag Breast Center Medical Director and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery and Nirav Savalia, M.D., Director of Oncoplastic and Aesthetic Breast Surgery at Hoag, were among the faculty selected by the American Society of Breast Surgeons to teach the Annual Oncoplastic Breast Surgery Course at the national meeting held this year in Las Vegas on April 26-30, 2017.This prestigious opportunity allowed Drs. Silverstein and Savalia to discuss and teach the Split Reduction, an operative technique developed and perfected at Hoag, for surgeons across the nation. Combining the principles of oncologic surgery with the techniques of plastic surgery, this technique alters the incision site on a patient’s breast to accommodate tumors that other oncologists said could not be removed without a mastectomy.“Hoag is the most advanced place in the world for saving breasts for patients who are told they need a mastectomy,” Dr. Silverstein said.“Women have so many treatment options, including lumpectomies and oncoplastic surgery to remove cancerous tumors while achieving optimal cosmetic and oncologic results. It is surprising that mastectomy is still the default surgical option for breast cancer treatment,” Dr. Savalia added.In addition, five research poster presentations were presented at the national meeting by Hoag faculty and USC/Hoag Breast Fellows on the following topics:A Comparison of Margin Width in DCIS Patients Treated with Breast Conserving Surgery Plus Whole Breast Radiation Therapy. Data supported the Consensus Guideline: 2 mm is an appropriate minimal margin width for patients with DCIS patients treated with breast conserving therapy plus whole breast radiation therapy. Analysis of data found a higher local recurrence rate with narrow surgical margins ( Click here to view the list of recent Press Releases from Hoag Memorial Hospital Presbyterian


Global Breast Imaging Market Shows Positive Signs of Growth During the Forecast Period 2017-2022 Breast imaging is the screening of the breast to detect cancer at various levels. The report highlights a significant growth for the market at a positive CAGR during the forecast period 2017-2022. Albany, NY, May 06, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1037516 Breast imaging is the screening of the breast to detect cancer at various levels. Breast cancer is a major type of cancer which is the cause of a mass death percentage; therefore, its early detection and effective medication need to be done with proper awareness to eradicate the problem. Breast imaging may range from Mammography, Tomosynthesis, Xeromammography, Galactography, Breast MRI, Breast ultrasound and others. The report starts with the overview of breast imaging market detailing product overview and its scope. The report further segments the market by breast imaging types such as analog breast imaging equipment and digital breast imaging equipment, providing comparison analysis of their production, CAGR and market share. Breast imaging application is also reported with their consumption comparison for the period 2012-2022. The applications listed include- General Surgery, Breast Surgery, and Physical examination. On the geographical scale, global breast imaging market is compared for market status and prospect for 2012-2022. The regions compared in the report include North America, Europe, China, Japan, Southeast Asia and India. Further, the breast imaging market competition is reported on the global scale for 2012-2017, along with its concentration rate, mergers & acquisitions, and expansion. Top players in the field include: · GE Healthcare · Siemens · Hologic · Philips Healthcare · Toshiba · Dilon Technologies · Gamma Medica · Sonocine · Fujifilm · Aurora Imaging Technology Further, a detailed comparison analysis is done to display supply, consumption, export, import by region; production, revenue, price trend by type and lastly market share, growth rate, market drivers & opportunities by the application. Browse Full Report with TOC: http://www.marketresearchhub.com/report/global-breast-imaging-market-research-report-2017-report.html The report concludes by offering breast imaging manufacturing cost analysis covering key raw material, price trend and proportion of manufacturing cost structure. Moreover, details of raw material, labor cost and manufacturing expenses can also be analyzed. The reader can also learn about the future consequences that may affect the market growth. These are mentioned under market effect factors analysis that constitutes technology risk, consumer preference change and environmental/political environmental change. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Details: 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Website: http://www.marketresearchhub.com/ Follow Us on: Twitter: https://twitter.com/MktResearchHub/ LinkedIn: https://www.linkedin.com/company/market-research-hub/ Facebook: https://www.facebook.com/MarketResearchHub/ Albany, NY, May 06, 2017 --( PR.com )-- The surging unhealthy lifestyle of the young generation and effects of adulteration, have led to the rising number of breast cancer problems at the global level. To give detailed insight and forecasted growth of the breast imaging market, Market Research Hub (MRH) has added a report titled “Global Breast Imaging Market Research Report 2017” to its wide database. The report highlights a significant growth for the market at a positive CAGR during the forecast period 2017-2022.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1037516Breast imaging is the screening of the breast to detect cancer at various levels. Breast cancer is a major type of cancer which is the cause of a mass death percentage; therefore, its early detection and effective medication need to be done with proper awareness to eradicate the problem. Breast imaging may range from Mammography, Tomosynthesis, Xeromammography, Galactography, Breast MRI, Breast ultrasound and others.The report starts with the overview of breast imaging market detailing product overview and its scope. The report further segments the market by breast imaging types such as analog breast imaging equipment and digital breast imaging equipment, providing comparison analysis of their production, CAGR and market share. Breast imaging application is also reported with their consumption comparison for the period 2012-2022. The applications listed include- General Surgery, Breast Surgery, and Physical examination.On the geographical scale, global breast imaging market is compared for market status and prospect for 2012-2022. The regions compared in the report include North America, Europe, China, Japan, Southeast Asia and India. Further, the breast imaging market competition is reported on the global scale for 2012-2017, along with its concentration rate, mergers & acquisitions, and expansion. Top players in the field include:· GE Healthcare· Siemens· Hologic· Philips Healthcare· Toshiba· Dilon Technologies· Gamma Medica· Sonocine· Fujifilm· Aurora Imaging TechnologyFurther, a detailed comparison analysis is done to display supply, consumption, export, import by region; production, revenue, price trend by type and lastly market share, growth rate, market drivers & opportunities by the application.Browse Full Report with TOC: http://www.marketresearchhub.com/report/global-breast-imaging-market-research-report-2017-report.htmlThe report concludes by offering breast imaging manufacturing cost analysis covering key raw material, price trend and proportion of manufacturing cost structure. Moreover, details of raw material, labor cost and manufacturing expenses can also be analyzed. The reader can also learn about the future consequences that may affect the market growth. These are mentioned under market effect factors analysis that constitutes technology risk, consumer preference change and environmental/political environmental change.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Details:90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.comWebsite: http://www.marketresearchhub.com/Follow Us on:Twitter: https://twitter.com/MktResearchHub/LinkedIn: https://www.linkedin.com/company/market-research-hub/Facebook: https://www.facebook.com/MarketResearchHub/ Click here to view the list of recent Press Releases from Market Research Hub


Healthcare and Business Leaders Meet to Discuss North Carolina Healthcare Industry Trends at Executive Event Raleigh, NC, December 11, 2016 --( The 2017 NC CEO Forum will span two days, and will feature a compelling speaker series and panels to discuss how research, policy, regulation, scientific discovery and the economics of healthcare impact the business of medicine. The keynote speakers addressing the forum include: · Michael Kastan, M.D., PhD., Executive Director of the Duke Cancer Institute · Dr. Kevin Campbell, Cardiologist and CEO of KROC Consulting · Kimberly Blackwell, M.D., Professor of Medicine and Assistant Professor, Duke University Medical Center · Dr. Daniel George, Professor of Medicine and Surgery, Oncology and Urology, Duke University School of Medicine · Dr. Shelley Hwang, Vice Chair of Research, Department of Surgery and Chief of Breast Surgery and Professor, Duke University · Brad Wilson, President and CEO, Blue Cross and Blue Shield of North Carolina · Joe Laurin, President, Fidelity Health Group · Frank Holding Jr., Chairman and CEO, First Citizens Bank · Jack Bailey, President of US Pharmaceuticals at GlaxoSmithKline · Neal Fowler, CEO of Liquidia · Steve Malik, Executive Chairman of Medfusion · Donald Gintzig, President & CEO of WakeMed Health & Hospitals · Zaher El-Assi, Vice President of Sales Transformation, IBM Watson Health · Fran O’Sullivan, Sr. State Executive for NC, IBM at RTP · Glen Tullman, CEO at Livongo Health The 2017 NC CEO Forum title sponsors include Blue Cross and Blue Shield of North Carolina, EDM Americas, Fidelity Investments, First Citizens Bank, and Quintiles IMS Health. The Triangle Business Journal is the Official Media Partner for this year’s event. Net proceeds from the event will go to the event’s featured nonprofits, Make-A-Wish Foundation of Eastern North Carolina and Teen Cancer America. Make-A-Wish Foundation of Eastern North Carolina grants the wishes of children with life-threatening medical conditions to allow children of all ages to fulfill their lifelong dreams. Teen Cancer America is an organization that partners with hospitals throughout the United States to develop specialized facilities and services for teens and young adults with cancer. For more information on the 2017 NC CEO Forum, including a complete agenda, visit http://www.ncceoforum.com/ Quotes: “This year’s forum features dynamic industry leaders who initiate change and innovation around North Carolina’s healthcare industry both regionally and abroad,” said Brian Kinahan, co-founder of the NC CEO Forum. “As we continue to develop North Carolina’s business sectors and review its impact on the overall healthcare industry, it is necessary to converge and converse about how to spur innovation and remain a leader in healthcare.” New Media Content: 2017 NC CEO Forum Twitter account: https://twitter.com/ncceoforum 2017 NC CEO Forum LinkedIn account: https://www.linkedin.com/groups/4540191 About The NC CEO Forum: The NC CEO Forum, founded by Rick Deckelbaum and Brian Kinahan, is an exclusive gathering of executives and management teams who want to gain a competitive edge in an increasingly crowded marketplace. Since 2009, the Forum has welcomed business, government and nonprofit leaders committed to helping North Carolina grow jobs and build a commanding presence on the national and international scene. The event has featured notable speakers such as retired U.S. Army four-star general and former U.S. Secretary of State Colin Powell; Arianna Huffington, chair, president and editor-in-chief of Huffington Post Media Group; Gen. Keith B. Alexander, CEO of IronNet Cybersecurity, the retired commander of U.S. Cyber Command and the retired director of the National Security Agency and Central Security Service; famed CEO Jack Welch; acclaimed business author Jim Collins; Ben Cohen and Jerry Greenfield, the iconic founders of Ben & Jerry’s ice cream; and Steve Forbes, chairman and CEO of Forbes and editor-in-chief of Forbes magazine, among others. In addition to improving the state’s business climate, the Forum donates net proceeds from the event each year to a chosen nonprofit partner. For more information on the NC CEO Forum, visit http://www.ncceoforum.com Raleigh, NC, December 11, 2016 --( PR.com )-- The NC CEO Forum is pleased to announce the 2017 theme – Innovation and Leadership in Healthcare. This executive education event will host over 400 senior business, government and nonprofit leaders to discuss the changes and innovations in healthcare and will include presentations and conversations with North Carolina’s top leaders in business and medicine. The event will be held over two half-day sessions on Thursday, Feb. 2 and Friday, Feb. 3, 2017 at the North Ridge Country Club in Raleigh.The 2017 NC CEO Forum will span two days, and will feature a compelling speaker series and panels to discuss how research, policy, regulation, scientific discovery and the economics of healthcare impact the business of medicine. The keynote speakers addressing the forum include:· Michael Kastan, M.D., PhD., Executive Director of the Duke Cancer Institute· Dr. Kevin Campbell, Cardiologist and CEO of KROC Consulting· Kimberly Blackwell, M.D., Professor of Medicine and Assistant Professor, Duke University Medical Center· Dr. Daniel George, Professor of Medicine and Surgery, Oncology and Urology, Duke University School of Medicine· Dr. Shelley Hwang, Vice Chair of Research, Department of Surgery and Chief of Breast Surgery and Professor, Duke University· Brad Wilson, President and CEO, Blue Cross and Blue Shield of North Carolina· Joe Laurin, President, Fidelity Health Group· Frank Holding Jr., Chairman and CEO, First Citizens Bank· Jack Bailey, President of US Pharmaceuticals at GlaxoSmithKline· Neal Fowler, CEO of Liquidia· Steve Malik, Executive Chairman of Medfusion· Donald Gintzig, President & CEO of WakeMed Health & Hospitals· Zaher El-Assi, Vice President of Sales Transformation, IBM Watson Health· Fran O’Sullivan, Sr. State Executive for NC, IBM at RTP· Glen Tullman, CEO at Livongo HealthThe 2017 NC CEO Forum title sponsors include Blue Cross and Blue Shield of North Carolina, EDM Americas, Fidelity Investments, First Citizens Bank, and Quintiles IMS Health. The Triangle Business Journal is the Official Media Partner for this year’s event.Net proceeds from the event will go to the event’s featured nonprofits, Make-A-Wish Foundation of Eastern North Carolina and Teen Cancer America. Make-A-Wish Foundation of Eastern North Carolina grants the wishes of children with life-threatening medical conditions to allow children of all ages to fulfill their lifelong dreams. Teen Cancer America is an organization that partners with hospitals throughout the United States to develop specialized facilities and services for teens and young adults with cancer.For more information on the 2017 NC CEO Forum, including a complete agenda, visit http://www.ncceoforum.com/Quotes:“This year’s forum features dynamic industry leaders who initiate change and innovation around North Carolina’s healthcare industry both regionally and abroad,” said Brian Kinahan, co-founder of the NC CEO Forum. “As we continue to develop North Carolina’s business sectors and review its impact on the overall healthcare industry, it is necessary to converge and converse about how to spur innovation and remain a leader in healthcare.”New Media Content:2017 NC CEO Forum Twitter account:https://twitter.com/ncceoforum2017 NC CEO Forum LinkedIn account:https://www.linkedin.com/groups/4540191About The NC CEO Forum:The NC CEO Forum, founded by Rick Deckelbaum and Brian Kinahan, is an exclusive gathering of executives and management teams who want to gain a competitive edge in an increasingly crowded marketplace. Since 2009, the Forum has welcomed business, government and nonprofit leaders committed to helping North Carolina grow jobs and build a commanding presence on the national and international scene. The event has featured notable speakers such as retired U.S. Army four-star general and former U.S. Secretary of State Colin Powell; Arianna Huffington, chair, president and editor-in-chief of Huffington Post Media Group; Gen. Keith B. Alexander, CEO of IronNet Cybersecurity, the retired commander of U.S. Cyber Command and the retired director of the National Security Agency and Central Security Service; famed CEO Jack Welch; acclaimed business author Jim Collins; Ben Cohen and Jerry Greenfield, the iconic founders of Ben & Jerry’s ice cream; and Steve Forbes, chairman and CEO of Forbes and editor-in-chief of Forbes magazine, among others. In addition to improving the state’s business climate, the Forum donates net proceeds from the event each year to a chosen nonprofit partner. For more information on the NC CEO Forum, visit http://www.ncceoforum.com Click here to view the list of recent Press Releases from 2017 NC CEO Forum


News Article | May 9, 2017
Site: www.eurekalert.org

DALLAS - May 8, 2017 - UT Southwestern Medical Center researchers found in a recent phase one clinical trial that stereotactic partial breast radiation was as safe as traditional radiation but decreased treatment time from six weeks to just days. UT Southwestern's Harold C. Simmons Comprehensive Cancer Center is the only site in Texas and one of a few in the world to offer stereotactic partial breast radiation treatment to early-stage breast cancer patients. "Standard breast cancer treatments are delivered daily to the entire breast area over three to six weeks. We sought to deliver partial breast radiation in a noninvasive way, using precise image-guided stereotactic radiation," said Dr. Asal Rahimi, Assistant Professor of Radiation Oncology and first author of the study. "Our trial decreased treatment time to just five treatments delivered every other day." Seventy-five patients were studied from 2010-2016, in whom stereotactic partial breast radiation demonstrated both outstanding tumor control and excellent cosmetic results. Patients in the trial had been recently diagnosed with early-stage breast cancer. The study is published in the International Journal of Radiation Oncology, Biology and Physics and was funded by a grant from Accuray, producers of the Cyberknife used to deliver stereotactic partial breast radiation. One of the trial participants is Dr. Rahimi's patient Leslie LeBlanc, a dental hygienist and resident of Arlington, Texas. Mrs. LeBlanc was diagnosed with early-stage breast cancer four years ago at age 47. Her daughter had just started college and her son was in high school. "The same day that I got the diagnosis was mother's weekend for my daughter at college. I drove straight to Austin and told her the news," said Mrs. LeBlanc, who recalled the shock of being diagnosed. "It's like you're in the eye of a hurricane. Everything is buzzing around you, but you can't do anything but what they ask you to do, or tell you is the best option." While no genetic link has been established, her two sisters had previously been diagnosed with breast cancer, so the family had some experience with the disease. Mrs. LeBlanc was already in a risk assessment program at UT Southwestern and had mammograms and MRIs every six months, which helped catch her disease early. "It was overwhelming to consider doing several weeks of daily radiation while trying to work fulltime, be with my family, and do everything that I needed to do. This treatment option was so much better. I only missed a few days from work," said Mrs. LeBlanc, who is looking forward to reaching her 5-year mark as a survivor next year. "Mrs. LeBlanc is a working woman, a mom, and a wife. She's a great example of many women that will be impacted by this disease," said Dr. Rahimi. "We wanted to make this treatment more convenient for patients, because cancer is never convenient." The researchers plan continued studies of the partial breast radiation technique. "As technology improves, we will detect more early-stage breast cancers." said Dr. Robert Timmerman, Professor of Radiation Oncology and senior author on the study. "Patients with these early cancers might particularly benefit from a local therapy approach that both minimizes the normal tissue exposure while improving the convenience for patients who already lead hectic lives." According to the National Cancer Institute, 252,710 women will be diagnosed with breast cancer this year. When breast cancer is found early before it has spread, the patient has an improved chance of surviving five years after being diagnosed. For breast cancer I females, 61.8 percent are diagnosed at the local stage. The 5-year survival for localized breast cancer in women is 98.9 percent. Stereotactic partial breast radiation is delivered with the latest generation CyberKnife, one of several technologies in UT Southwestern's newly opened $66 million, 63,000-square-foot Radiation Oncology facility. The new facility houses a comprehensive mix of UT Southwestern's best cancer treatment technologies and medical expertise under one roof, and has dedicated areas for each major disease site such as brain, breast, and gastrointestinal cancer. Additional UT Southwestern researchers involved in the study include: Dr. Ann Spangler, Associate Professor of Radiation Oncology; Dr. Roshni Rao, Associate Professor of Surgery; Dr. Marilyn Leitch, Professor of Surgery; Dr. Rachel Wooldridge, Assistant Professor of Surgery; Dr. Aeisha Rivers, Assistant Professor of Surgery; Dr. Stephen Seiler, Assistant Professor of Radiology; Dr. Kevin Albuquerque, Associate Professor of Radiation Oncology; Dr. Sally Goudreau, Professor of Radiology; Dr. Barbara Haley, Professor of Internal Medicine; Dr. David Euhus, (former faculty); Dr. Chuxiong Ding, Associate Professor of Radiation Oncology; and Dr. Chul Ahn, Professor of Clinical Sciences. Dr. Timmerman holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research. Dr. Leitch holds the S.T. Harris Family Distinguished Chair in Breast Surgery, in Honor of A. Marilyn Leitch, M.D. Dr. Haley holds the Charles Cameron Sprague, M.D., Chair in Clinical Oncology. The Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 47 NCI-designated Comprehensive Cancer Centers in the nation. Simmons Comprehensive Cancer Center includes 13 major cancer care programs. In addition, the Center's education and training programs support and develop the next generation of cancer researchers and clinicians. Simmons Comprehensive Cancer Center is among only 30 U.S. cancer research centers to be designated by the NCI as a National Clinical Trials Network Lead Academic Participating Site. UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 18 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.


News Article | October 28, 2016
Site: www.prweb.com

A total of 28 Mercy Medical Center physicians were recognized in Baltimore magazine’s November 2016 “Top Docs” issue, representing 23 separate specialties, ranging from breast cancer surgery to varicose veins. They are (as listed in the magazine): Dr. Kelly Alexander, General Surgery Dr. Mark Applefeld, Cardiology: Interventional Dr. Fermin Barrueto, Urogynecology Dr. John Campbell, Orthopedic Surgery: Foot & Ankle Dr. Bernard W. Chang, Plastic Surgery: Reconstructive and Plastic Surgery: Breast Dr. Teresa Diaz-Montes, Gynecologic Oncology Dr. Susan Dulkerian, Neonatology Dr. R. Mark Ellerkmann, Gynecology: General Dr. J. Lawrence Fitzpatrick, General Surgery Dr. Neil B. Friedman, Breast Surgery and Oncology: Breast Dr. Scott Huber, Gastroenterology Dr. Dwight D. Im, Gynecologic Oncology Dr. Maria Jacobs, Radiation Oncology Dr. Clifford Jeng, Orthopedic Surgery: Foot & Ankle Dr. Peter Ledakis, Oncology: General Dr. Paul Lucas, Surgery for Chronic Venous Disease/Varicose Veins Dr. Lynn Ludmer, Rheumatology Dr. David Maine, Pain Management Dr. Andrea Marx, Rheumatology Dr. Albert Polito, Pulmonary Dr. Neil B. Rosenshein, Gynecologic Oncology Dr. John Salkeld, Radiology: Nuclear Medicine Dr. Armando Sardi, Surgical Oncology Dr. David Sill, Interventional Radiology Dr. Amish Sura, Cardiology: Interventional Dr. Thomas Swope, General Surgery Dr. Debra Vachon, ColoRectal Dr. Linda C. Wang, Dermatology (Medical) Mercy’s Dr. Maria C.E. Jacobs, Director of Radiation Oncology, was among several doctors photographed and profiled for the special edition. Dr. Jacobs works in close collaboration with the cancer surgeons, including fellow Baltimore magazine “Top Doc” honoree, Dr. Neil B. Friedman, Director, The Hoffberger Breast Center to coordinate post surgical treatment for breast cancer patients. Dr. Jacobs and Dr. Friedman were the first team of doctors in the state of Maryland to use Intraoperative Radiotherapy (IORT), a state-of-the-art technology that allows patients to get treated in one single radiation therapy session – a notable advantage over the many multiple visits required prior to IORT. Each Mercy physician was recognized as among the best in their respective fields. Other honorees including Dr. Dwight Im, Dwight D. Im, M.D., FACOG, renowned gynecologic cancer surgeon and leader of Mercy Medical Center’s prestigious gynecology and robotic surgery programs, and been named a “Top Doctor" for 2016 earlier this year by Castle Connolly Medical Ltd.; Armando Sardi, M.D., FACS, respected and renowned Surgical Oncologist who has been honored as a Top Doc in Baltimore magazine multiple times, serves as Medical Director of The Institute for Cancer Care at Mercy and as Chief of Division of Surgical Oncology at Mercy and recognized internationally for his work in the field of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat late stage, complex cancers of the abdominal region; and Teresa P. Diaz-Montes, M.D., MPH, FACOG, Associate Director of The Lya Segall Ovarian Cancer Institute, the first center in the region specifically designed for the treatment of ovarian cancer. Mercy Medical Center in Baltimore, MD, is a 142-year-old university affiliated medical facility named a "Top Hospital" by U.S. News and World Report with a national reputation for women's health care. For more information about Mercy, visit Mercy online at http://www.mdmercy.com; MDMercyMedia on FACEBOOK and TWITTER; or call 1-800-MD-MERCY.


Newport Beach, CA, December 08, 2016 --( Oncoplastic surgery combines plastic surgery techniques with evidence-based cancer removal principles to leave women both tumor-free and whole. Dr. Savalia, who is also a clinical assistant professor of surgery at Keck School of Medicine of USC, developed novel techniques in oncoplastic surgery that have been presented nationally. “Dr. Savalia is a highly skilled, dedicated surgeon who understands the complexity of cancer treatment from a physiological, psychological and aesthetic standpoint. He is a champion of women’s health and is a great leader,” said Melvin J. Silverstein, M.D., Hoag Breast Center Medical Director and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery. “We are excited to have him direct our efforts at Hoag.” Board certified in plastic surgery, Dr. Savalia is a firm believer in helping women maintain their breasts while working to rid their bodies of cancer. His goal, he said, is to educate women against the rising tide of unnecessary mastectomies that have become the default mode for too many cancer patients. “Women have so many treatment options, including lumpectomies and oncoplastic surgery to remove cancerous tumors while achieving optimal cosmetic and oncologic results. It is surprising that mastectomy is still the default surgical option for breast cancer treatment,” Dr. Savalia said. “Hoag has long championed options that benefit women’s health. It is very exciting to me to be a part of this progressive, patient-centered team.” In his new role, Dr. Savalia will lead the development of a comprehensive breast reconstruction program at Hoag, developing a reconstruction database to track and study outcomes. He will also train USC breast fellows on oncoplastic surgery. A respected surgeon who has published several peer-reviewed papers about innovative surgical techniques, Dr. Savalia offers a level of professionalism and expertise that patients expect of Hoag. “Dr. Savalia is able to communicate what too few surgeons do, which is that breast cancer doesn’t have to ‘win’ the war against a woman’s body,” Dr. Silverstein said. “His level of skill, innovation and commitment to patients makes us proud to call Dr. Savalia one of our own.” About Hoag Memorial Hospital Presbyterian Hoag is an approximately $1 billion nonprofit, regional health care delivery network in Orange County, California, that treats more than 27,000 inpatients and 379,000 outpatients annually. Hoag consists of two acute-care hospitals – Hoag Hospital Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 – in addition to seven health centers and ten urgent care centers. Hoag is a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). Hoag offers a comprehensive blend of health care services that includes five institutes providing specialized services in the following areas: cancer, heart and vascular, neurosciences, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and two ambulatory surgical centers. In 2013, Hoag entered into an alliance with St. Joseph Health to further expand health care services in the Orange County community, known as St. Joseph Hoag Health. Hoag has been named one of the Best Regional Hospitals in the 2016 - 2017 U.S. News & World Report, and Becker’s Hospital Review named Hoag as one of the 2016 “100 Great Hospitals in America” – a designation Hoag has received four times. National Research Corporation has endorsed Hoag as Orange County’s most preferred hospital for the past 20 consecutive years and, for an unprecedented 21 years, residents of Orange County have chosen Hoag as one of the county’s best hospitals in a local newspaper survey. Visit www.hoag.org for more information. Newport Beach, CA, December 08, 2016 --( PR.com )-- Underscoring its commitment to innovation in women’s health, Hoag Memorial Hospital Presbyterian announced it has named Nirav Savalia, M.D., to serve as Director of Oncoplastic and Aesthetic Breast Surgery.Oncoplastic surgery combines plastic surgery techniques with evidence-based cancer removal principles to leave women both tumor-free and whole. Dr. Savalia, who is also a clinical assistant professor of surgery at Keck School of Medicine of USC, developed novel techniques in oncoplastic surgery that have been presented nationally.“Dr. Savalia is a highly skilled, dedicated surgeon who understands the complexity of cancer treatment from a physiological, psychological and aesthetic standpoint. He is a champion of women’s health and is a great leader,” said Melvin J. Silverstein, M.D., Hoag Breast Center Medical Director and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery. “We are excited to have him direct our efforts at Hoag.”Board certified in plastic surgery, Dr. Savalia is a firm believer in helping women maintain their breasts while working to rid their bodies of cancer. His goal, he said, is to educate women against the rising tide of unnecessary mastectomies that have become the default mode for too many cancer patients.“Women have so many treatment options, including lumpectomies and oncoplastic surgery to remove cancerous tumors while achieving optimal cosmetic and oncologic results. It is surprising that mastectomy is still the default surgical option for breast cancer treatment,” Dr. Savalia said. “Hoag has long championed options that benefit women’s health. It is very exciting to me to be a part of this progressive, patient-centered team.”In his new role, Dr. Savalia will lead the development of a comprehensive breast reconstruction program at Hoag, developing a reconstruction database to track and study outcomes. He will also train USC breast fellows on oncoplastic surgery.A respected surgeon who has published several peer-reviewed papers about innovative surgical techniques, Dr. Savalia offers a level of professionalism and expertise that patients expect of Hoag.“Dr. Savalia is able to communicate what too few surgeons do, which is that breast cancer doesn’t have to ‘win’ the war against a woman’s body,” Dr. Silverstein said. “His level of skill, innovation and commitment to patients makes us proud to call Dr. Savalia one of our own.”About Hoag Memorial Hospital PresbyterianHoag is an approximately $1 billion nonprofit, regional health care delivery network in Orange County, California, that treats more than 27,000 inpatients and 379,000 outpatients annually. Hoag consists of two acute-care hospitals – Hoag Hospital Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 – in addition to seven health centers and ten urgent care centers. Hoag is a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). Hoag offers a comprehensive blend of health care services that includes five institutes providing specialized services in the following areas: cancer, heart and vascular, neurosciences, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and two ambulatory surgical centers. In 2013, Hoag entered into an alliance with St. Joseph Health to further expand health care services in the Orange County community, known as St. Joseph Hoag Health. Hoag has been named one of the Best Regional Hospitals in the 2016 - 2017 U.S. News & World Report, and Becker’s Hospital Review named Hoag as one of the 2016 “100 Great Hospitals in America” – a designation Hoag has received four times. National Research Corporation has endorsed Hoag as Orange County’s most preferred hospital for the past 20 consecutive years and, for an unprecedented 21 years, residents of Orange County have chosen Hoag as one of the county’s best hospitals in a local newspaper survey. Visit www.hoag.org for more information. Click here to view the list of recent Press Releases from Hoag Memorial Hospital Presbyterian


News Article | March 1, 2017
Site: www.prweb.com

Breast Surgeon, Dr. Dennis Holmes of 90210 Surgery Medical Center will review minimally invasive cryoablation for the treatment of early stage breast cancer and where it fits in the treatment paradigm at Susan G. Komen San Diego’s Annual Dinner Symposium, “Screens, Genes & The Choices We Make.” The event brings together leading cancer and wellness experts to share the latest innovations in breast cancer research, treatment and holistic well-being. The symposium will take place on Thursday, March 16, 2017 at the San Diego Del Mar Marriott. Dr. Holmes is an internationally renowned breast surgeon and cancer researcher currently serving as Interim Director of the Margie Petersen Breast Center at Providence St. John’s Health Center and Interim Director, John Wayne Cancer Institute Breast Surgery Fellowship Program. Formerly, Dr. Holmes held the positions of Chief Breast Surgeon and Medical Director of the Los Angeles Center for Women’s Health, and Chief Breast Cancer Surgeon, and Breast Cancer Research Committee Co-Chair at the University of Southern California Kenneth Norris Comprehensive Cancer Center. Dr. Holmes has been a pioneer in the field of minimally invasive breast surgery, including intraoperative radiotherapy, lymph node-sparing surgery and cryoablation “I am thrilled to partner with Komen San Diego, as we share similar goals - to save lives and pursue the best breast cancer treatments,” said Dr. Holmes. Currently, the standard of care for early stage breast cancer is surgery (e.g. lumpectomy, mastectomy) and sentinel node biopsy followed by breast radiotherapy and adjuvant endocrine and/or chemotherapy. Although surgery offers tumor removal and margin verification, a major drawback of surgery is the cosmetic and functional impairment of the breast resulting from volume changes, scar formation, nipple displacement, sensation changes, skin/scar retraction, and re-excision rate. Dr. Holmes was an investigator in the National Cancer Institute Z1072 Clinical Trial sponsored by the Alliance for Clinical Trials in Oncology. The trial examined cryoablation for the treatment of early stage breast cancer. In a 5-year multicenter study, cryoablation was shown to be 92% effective for complete ablation of invasive breast tumors ≤2 cm and 100% effective for complete ablation of invasive ductal breast cancer tumors <1.0 cm. Results from this breast cancer study (ACOSOG Z1072), which included a 5-year follow-up, were published in the Annals of Surgical Oncology. The Visica® 2 Treatment System developed by Sanarus Technologies, was the exclusive device used in the Z1072 study. “Cryoablation is a very promising alternative to traditional surgery for early stage breast cancer. Cryoablation minimizes changes in breast volume and nipple position, and avoids prominent scars,” explained Dr. Holmes. “The outstanding results of Z0172 inspired me to start the FROST Clinical Study, for which I now serve as Principal Investigator.” The FROST Clinical Study is the evolution of data from Z1072, which examines the rate of successful tumor ablation in patients treated with cryoablation of the primary tumor instead of surgical removal of early stage breast cancer. The FROST Clinical Study is currently enrolling women age 50 and older with core needle biopsy proven clinical stage I, T1, (≤1.5 cm) clinically node negative (N0), unifocal, hormone receptor positive and HER2/neu-negative invasive ductal carcinoma. Cryoablation with the Visica 2 Treatment System is a nonsurgical option for patients that have been diagnosed with early stage breast cancer, is visible on sonogram, and has been confirmed with a biopsy. This procedure has many benefits including: under 30-minutes, local anesthesia, in-office, excellent cosmesis, cost efficient, and quick patient recovery. Cryoablation is a viable option to surgery that results in complete early stage tumor ablation. About Dr. Holmes Dr. Holmes serves in the leadership of several national surgical societies and is a frequent lecturer at national conferences. He is a member of the education committee of the American Society of Breast Surgeons. Dr. Holmes is a Fellow of the American College of Surgeons and was also recently selected as Board Chair and President of the TARGIT Collaborative Group, a national research and education organization. Widely respected by colleagues for his innovative approach to breast cancer care, Dr. Holmes has gained worldwide acclaim for his pioneering research in targeted intraoperative radiotherapy. Dr. Holmes believes wholeheartedly that, with proper treatment, most women diagnosed with breast cancer will live a long, fulfilling life—a life both richer and more meaningful than they could have ever imagined. Find out more at http://www.drholmesmd.com About Sanarus Technologies In 2001, the Visica® 2 Treatment System was the first device available for cryoablation of fibroadenomas. Since then, our system has been used to successfully treat thousands of patients. The Visica 2 Treatment System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. At Sanarus, we develop innovative solutions for the nonsurgical treatment of breast tumors. We are headquartered in Pleasanton, CA, and all our products are manufactured in the USA. Find out more at http://www.sanarus.com ABOUT SUSAN G. KOMEN SAN DIEGO®: Since its inception in 1995, Komen San Diego has granted more than $18 million to research and local non-profits who provide everything from free diagnostic mammograms, meal delivery, temporary financial aid, transportation and more. Seventy-five percent of every dollar raised in San Diego stays in San Diego County to fund breast health services for uninsured and underinsured women and their families. The remaining 25 percent funds international breast cancer research. In fact, next to the U.S. government, Susan G. Komen® is the largest funder of breast cancer research in the world. For more information, please visit http://www.komensandiego.org. Connect with us on Facebook and Twitter and Instagram.


DALLAS--(BUSINESS WIRE)--The 2016 recipients of the Brinker Awards for Scientific Distinction will be recognized for their vital contributions to research today at the prestigious 39th annual San Antonio Breast Cancer Symposium (SABCS). Charles Perou, Ph.D. and Monica Morrow, M.D., FACS, will both deliver keynote lectures during the symposium, and will be honored at a reception this evening. Established by Komen in 1992, the Brinker Awards for Scientific Distinction recognize the efforts of pioneers in two critically important areas of the fight to end breast cancer: Clinical Research and Basic Science. This year’s winners join the ranks of an esteemed group of scientists who have been recognized for advancing breast cancer research and medicine with the Brinker Awards – the highest scientific honor awarded by Susan G. Komen, the world’s leading breast cancer organization. The 2016 Brinker Award for Scientific Distinction in Basic Science will be presented to Dr. Perou, the May Goldman Shaw Distinguished Professor of Molecular Oncology and Professor of Genetics and Pathology & Laboratory Medicine at the University of North Carolina School of Medicine and co-program leader of the breast cancer research program and member of the UNC Lineberger Comprehensive Cancer Center. Dr. Perou’s work has helped to characterize the diversity of breast tumors, demonstrating that breast cancers can be classified into at least five molecular subtypes. His work also led to the discovery of the basal-like/triple-negative breast cancer (TNBC) subtype. Further, he and his colleagues were among the first to discover that the breast cancer subtypes were of prognostic and predictive value, and to associate specific genetic mutations with specific breast cancer subtypes. Dr. Morrow, chief of the Breast Surgery Service and Anne Burnett Windfohr Chair of Clinical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Surgery at Weill Cornell Medical College, will receive the Brinker Award for Scientific Distinction in Clinical Research. Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer. More than 60 other Komen representatives including Scientific Advisory Board members, Komen Scholars and grantees will join Dr. Perou, Dr. Morrow and thousands of other leading physicians and researchers from around the globe at SABCS, contributing to discussions around experimental biology, etiology, prevention, diagnosis and therapy of breast cancer. Advancing breast cancer research has been a priority for Komen since opening its doors in 1982. To date, Komen has invested more than $920 million in breast cancer research, and is the largest nonprofit funder of breast cancer research outside of the U.S. government, currently funding nearly 300 research grants worldwide. Susan G. Komen is the world’s largest breast cancer organization outside of the federal government, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $920 million in research and provided more than $2 billion in funding to screening, education, treatment and psychosocial support programs. Komen has worked in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.


Galatea Also Announces First Outside the United States Clinical Use of GalaFLEX for Breast Surgery LEXINGTON, Massachusetts, Nov. 16,  2016 /PRNewswire/ -- Galatea Surgical, a wholly owned subsidiary of Tepha, Inc. focused on the Plastic and Aesthetic surgery market, announced today that clinical data supporting the use of its GalaFLEX™ Surgical Scaffold for mastopexy (i.e. breast lift) was presented at the London Breast Meeting by William P. Adams, MD of Dallas Texas.  Galatea also announced that the first surgical procedure utilizing GalaFLEX for an aesthetic breast surgical procedure outside the United States was performed by Patrick Mallucci, MD, FRCS, a leading London-based Plastic Surgeon.  The GalaFLEX Surgical Scaffold is made from a resorbable polymer called P4HB™, developed by Galatea's parent company, Tepha, Inc. Dr. Adams commented, "Mastopexy, or breast lift, is a good choice for the many women seeking a rejuvenated, perkier appearance, but without a breast implant; however, maintaining the surgical correction of ptosis (drooping) is often a challenge due to the weakened condition of the underlying breast tissue.  Our preliminary one year experience with GalaFLEX utilized to support the weakened tissue suggests that it can help to sustain our surgical correction with minimal risk to the patient." Mr. Mallucci added, "I am very excited about the opportunity to utilize the GalaFLEX Surgical Scaffold in a variety of my aesthetic breast procedures.  My first case went very smoothly and I was impressed with the ease of use and handling properties of the GalaFLEX mesh." The GalaFLEX Surgical Scaffold is based on Tepha's P4HB™, resorbable polymer technology. P4HB (poly-4-hydroxybutyrate) is a proprietary polymer with a unique biomechanical and biocompatibility profile that is ideal for soft tissue repair and support procedures. GalaFLEX Surgical Scaffold has a CE Mark (for European marketing) and is intended for use in breast surgery procedures for which soft tissue support may be needed to obtain the desired surgical result. About Tepha: Tepha Inc, founded in 1998 and headquartered in Lexington, MA, is a supplier of medical devices focused on the BioMaterials market. Tepha's products are designed and developed to elevate, support and reinforce areas of soft tissue weakness as well as to promote improved healing responses. To date Tepha and its partners have received 23 510(k) clearances for devices marketed in the US as well as five CE Marks for products sold in Europe. Commercial products based on Tepha's resorbable P4HB polymer technology include: high tensile strength sutures for orthopedic soft tissue repair; mesh constructs for ventral and inguinal hernia repair; monofilament sutures for abdominal wall closure and plastic surgery; patches for tendon and ligament repairs; and mesh constructs for face and breast lifts. To date, products made from P4HB have been successfully used in more than 1,000,000 surgical procedures worldwide, and have been the subject of over 30 published clinical and scientific papers. More information about the Company and its products can be found at its website www.Tepha.com and www.Galateasurgical.com.

Loading Breast Surgery collaborators
Loading Breast Surgery collaborators